Michael S Nakazawa, MD, PhD
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | University of Pennsylvania School of Medicine, Philadelphia, PA, USA, MD, Medicine |
| 2015 | University of Pennsylvania School of Medicine, Philadelphia, PA, USA, PHD, Medicine |
| 2008 | Columbia University, New York, NY, USA, BS, Engineering and Applied Science |
Board Certifications
| 2020 | American Board of Internal Medicine |
Selected Publications
Peer-Reviewed Articles
- Beird H*, Wu C*, Nakazawa MS*, Ingram D, Daniele J, Little L, Daw NB, Wani K, Lazcano R, Song X, Gumbs C, Zhang J, Rubin B, Conley AP, Flanaga A, Lazar AJ, Futreal A *Authors contributed equally. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. HGG Adv 4(4), 2023.
- Gade TPF, Tucker E, Nakazawa MS, Hunt SJ, Wong W, Krock B, Weber CN, Nadolski GJ, Clark TWI, Soulen MC, Furth EE, Winkler JD, Amaravadi RK, Simon MC. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 283(3):702-710, 2017. e-Pub 2017. PMID: 28253108.
- Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat Rev Cancer 16(10):663-73, 2016. PMID: 27658636.
- Nakazawa MS, Eisinger-Mathason TS, Sadri N, Ochocki JD, Gade TP, Amin RK, Simon MC. Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nat Commun 7:10539, 2016. e-Pub 2016. PMID: 26837714.
- Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S, Simon MC. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad Sci U S A 112(26):E3402-11, 2015. e-Pub 2015. PMID: 26080399.
- Krock BL, Eisinger-Mathason TS, Giannoukos DN, Shay JE, Gohil M, Lee DS, Nakazawa MS, Sesen J, Skuli N, Simon MC. The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability. Blood 125(21):3263-72, 2015. e-Pub 2015. PMID: 25855602.
- Mucaj V, Lee SS, Skuli N, Giannoukos DN, Qiu B, Eisinger-Mathason TS, Nakazawa MS, Shay JE, Gopal PP, Venneti S, Lal P, Minn AJ, Simon MC, Mathew LK. MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma. Oncogene 34(17):2204-14, 2015. e-Pub 2014. PMID: 24954504.
- Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 19(22):6173-82, 2013. e-Pub 2013. PMID: 24045179.
- Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JE, Stangenberg L, Sadri N, Puré E, Yoon SS, Kirsch DG, Simon MC. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov 3(10):1190-205, 2013. e-Pub 2013. PMID: 23906982.
- Wong WJ, Qiu B, Nakazawa MS, Qing G, Simon MC. MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Mol Cell Biol 33(17):3494-504, 2013. e-Pub 2013. PMID: 23816886.
- Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC, Yoon SS. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer 132(1):29-41, 2013. e-Pub 2012. PMID: 22684860.
- Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, Araujo D, Somaiah N, Ravi V, Nassif EF, Roland CL, Lazar AJ, Guadagnolo BA, Harrison DJ, Benjamin RS, Patel S, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: an MD Anderson Cancer Center case series. Cancers.
Abstracts
- Nakazawa MS, Silverman IM, Rimkunas V, Johnson A, Veloso A, Glodzik D, Zimmermann M, Yap T, Wang W, Livingston JA. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas. ASCO, 2023.
- Nakazawa MS, Cheng L, Ahmed M, Lazcano R, Wani K, Veiseh O, Kwong LN. Detecting and intervening on rare pre-existing resistant subclones to BRAF/MEK inhibitors in metastatic melanoma. AACR, 2023.
- Nakazawa MS, Livingston JA, Bishop AJ, Zarzour MA, Somaiah N, Ratan R, Gill JB, Urquiola E, Posey K, Guadagnolo BA, Gorlick RG, Benjamin RS, Patel S, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: an MD Anderson Cancer Center case series. ASCO, 2022.
- Nakazawa MS, Grogan T, Nichols N, Reiter R, Rettig M. Randomized, Open Label, Neoadjuvent Phase 2 Study Comparing the Effects of AR Inhibition with and without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer. UCLA DOM Research Day, 2018.
- Nakazawa MS. The role of epigenetic therapy in the treatment of sarcoma. University of Pennsylvania Combined Degree Program Annual Retreat, 2015.
- Nakazawa MS, Eisinger-Mathason TS, Sadri N, Ochocki JD, Gade TP, Amin RK, Simon MC. Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Keystone Hypoxia Meeting, 2015.